Clinical Trial Update: HKI-272 for HER2-Positive Breast Cancer and Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial update for neratinib (HKI-272) in HER2-positive breast cancer with brain metastases; the study completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• HKI-272 (neratinib) (neratinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-05-22